Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00141219
Status:
COMPLETED
Last Update Posted:
2021-02-09
First Post:
2005-08-30
Brief Title:
Pregabalin Peripheral Neuropathic Pain Study
Sponsor:
Pfizers Upjohn has merged with Mylan to form Viatris Inc
Organization:
Pfizer
Study Overview
Official Title:
A 10-Week Randomized Double-Blind Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Pregabalin 150 mg - 600 mgDay Using a Flexible Optimized Dose Schedule in Subjects With Peripheral Neuropathic Pain
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the efficacy of pregabalin using a flexible optimized dose schedule with dose adjustment based on Daily Pain Rating Scale DPRS compared to placebo in subjects with peripheral neuropathic pain
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None